Drug Profile
NMED 157
Latest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Neuromed Pharmaceuticals
- Class
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 25 Mar 2008 Discontinued - Preclinical for Stroke in Canada (unspecified route)
- 08 Mar 2006 Neuromed Technologies is now called Neuromed Pharmaceuticals
- 04 Mar 2003 NMED 157 is available for licensing (www.neuromedtech.com)